Table 2 Incidence of HCC by antiviral agents.
Patient group | PSM | Group | Total | Person-year | HCC (−) | HCC (+) | Incidence rate (95% CI) | Incidence rate ratio (95% CI) | P |
|---|---|---|---|---|---|---|---|---|---|
Total | Before PSM | BSV | 2358 | 5917.85 | 2301 (97.38) | 62 (2.62) | 9.63 (7.43–12.49) | 1 (ref) | |
TAF | 39,499 | 95107.72 | 38,322 (96.81) | 1262 (3.19) | 12.38 (11.69–13.10) | 1.28 (0.98–1.68) | 0.065 | ||
After PSM | BSV | 2239 | 5458.56 | 2186 (97.63) | 53 (2.37) | 9.71 (7.42–12.71) | 1 (ref) | ||
TAF | 6717 | 15918.10 | 6535 (97.29) | 182 (2.71) | 11.43 (9.89–13.22) | 1.18 (0.87–1.60) | 0.295 | ||
Non-cirrhosis | Before PSM | BSV | 1882 | 4764.86 | 1852 (98.41) | 30 (1.59) | 6.30 (4.40–9.00) | 1 (ref) | |
TAF | 31,216 | 75712.67 | 30,572 (97.94) | 644 (2.06) | 8.51 (7.87–9.19) | 1.35 (0.94–1.95) | 0.107 | ||
After PSM | BSV | 1782 | 4373.96 | 1755 (98.48) | 27 (1.52) | 6.17 (4.23–9.00) | 1 (ref) | ||
TAF | 5336 | 12743.37 | 5234 (98.09) | 102 (1.91) | 8.00 (6.59–9.72) | 1.30 (0.85–1.98) | 0.230 | ||
Cirrhosis | Before PSM | BSV | 476 | 1152.99 | 449 (94.33) | 27 (5.67) | 23.42 (16.06–34.15) | 1 (ref) | |
TAF | 8283 | 19395.04 | 7750 (93.57) | 533 (6.43) | 27.48 (25.24–29.92) | 1.17 (0.80–1.73) | 0.417 | ||
After PSM | BSV | 457 | 1084.60 | 431 (94.31) | 26 (5.69) | 23.97 (16.32–35.21) | 1 (ref) | ||
TAF | 1381 | 3174.73 | 1301 (94.21) | 80 (5.79) | 25.20 (20.24–31.37) | 1.05 (0.68–1.64) | 0.825 |
